1、Rb1、Rc、Rd、Re、Rf、Rg3、Rh1、Rb2和Rb3)在正常和慢性心力衰竭模型大鼠體內(nèi)的藥動(dòng)學(xué)規(guī)律與差異,為其臨床合理用藥提供參考。方法 12只Wistar大鼠隨機(jī)分為對(duì)照組和模型組,每組6只。采用冠狀動(dòng)脈結(jié)扎法建立慢性心衰大鼠模型,造模14 d后,兩組大鼠均iv給予YQFM 543 mg/kg。建立超高效液相色譜-質(zhì)譜聯(lián)用(UFLC-MS/MS)法,測(cè)定不同時(shí)間點(diǎn)各人參皂苷的血藥濃度,繪制藥時(shí)曲線,采用DAS 3.0藥動(dòng)學(xué)軟件計(jì)算藥動(dòng)學(xué)參數(shù),并進(jìn)行比較。結(jié)果 iv YQFM后,各皂苷成分在對(duì)照組和慢性心力衰竭模型組大鼠體內(nèi)的主要藥動(dòng)學(xué)參數(shù)T1/2、AUC0-t、AUC0-∞、CL等,均沒(méi)有顯著性差異。結(jié)論 在慢性心力衰竭狀態(tài)下,機(jī)體對(duì)YQFM中皂苷成分的代謝無(wú)明顯影響。;Objective To study the rule and difference of pharmacokinetics of ten ginsenosides (Rg1, Rb1, Rc, Rd, Re, Rf, Rg3, Rh1, Rb2 and Rb3) in Yiqi Fumai Lyophilized Injection (YQFM) in normal and chronic heart failure (CHF) model rats in vivo, and provide reference for clinical rational drug use. Method Totally twelve Wistar rats were randomly divided into control and model group (n=6), chronic heart failure model of rats was established by using coronary artery ligation method. At 14 d after modeling, all rats in the two groups were given iv administration of YQFM (543 mg/kg). The plasma concentration of ginsenosides at different time-points was analyzed by Ultra high performance liquid chromatography-mass spectrometry (UFLC-MS/MS), the drug-time curves were drawn and the pharmacokinetic parameters were calculated and compared by DAS 3.0 program. Results The main pharmacokinetic parameters of ginsenosides in the CHF model group, such as T1/2, AUC0-t, AUC0-∞, CLz, had no significant difference compared with control group after administration of YQFM. Conclusion The body has no significant effect on the metabolism of ginsenosides in the condition of chronic heart failure."/>